Literature DB >> 24128413

Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.

Grace Lai-Hung Wong1, Henry Lik-Yuen Chan1, Catherine Ka-Yan Wong2, Calvin Leung2, Candace Yim Chan2, Patricia Po-Lai Ho2, Vivian Chi-Yee Chung2, Zhan Cham-Yan Chan2, Yee-Kit Tse1, Angel Mei-Ling Chim1, Tina Kit-Ting Lau1, Vincent Wai-Sun Wong3.   

Abstract

BACKGROUND & AIMS: CU-HCC score is accurate to predict hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients. However, diagnosis of cirrhosis may be incorrect based on ultrasonography, leading to some errors in HCC prediction. This study aimed to evaluate the accuracy of LSM-HCC score, refined from CU-HCC score with liver stiffness measurement (LSM) using transient elastography to predict HCC.
METHODS: A prospective cohort study of 1555 consecutive CHB patients referred for transient elastography examination; 1035 and 520 patients randomly assigned to training and validation cohorts, respectively. Clinical cirrhosis of CU-HCC score was substituted by LSM and analyzed with multivariable Cox regression analysis with other parameters.
RESULTS: During a mean follow-up of 69 months, 38 patients (3.7%) in the training cohort and 17 patients (3.4%) in the validation cohort developed HCC. A new LSM-HCC score composed of LSM, age, serum albumin and hepatitis B virus (HBV) DNA levels were derived, which ranges from 0 to 30. Areas under receiver operating characteristic curves of LSM-HCC score were higher than those of CU-HCC score (0.83-0.89 vs. 0.75-0.81). By applying the cutoff value of 11, the score excluded future HCC with high negative predictive value (99.4%-100%) at 5 years.
CONCLUSIONS: LSM-HCC score constructed from LSM, age, serum albumin and HBV DNA level is accurate to predict HCC in CHB patients.
Copyright © 2013 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ALT; AUROC; Anti-HBe; CHB; CI; HBV; HBV DNA; HBeAg; HBsAg; HCC; HR; IQR; LSM; Liver-related mortality; Predication score; Transient elastography; alanine aminotransferase; antibody against hepatitis B e antigen; area under the receiver operating characteristics curve; chronic hepatitis B; confidence intervals; hazard ratios; hepatitis B e antigen; hepatitis B surface antigen; hepatitis B virus; hepatocellular carcinoma; interquartile range; liver stiffness measurement

Mesh:

Substances:

Year:  2013        PMID: 24128413     DOI: 10.1016/j.jhep.2013.09.029

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  59 in total

Review 1.  Critical comparison of elastography methods to assess chronic liver disease.

Authors:  Mireen Friedrich-Rust; Thierry Poynard; Laurent Castera
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

Review 2.  Surveillance of the Patients with High Risk of Hepatocellular Cancer.

Authors:  Necati Örmeci
Journal:  J Gastrointest Cancer       Date:  2017-09

3.  Surveillance for hepatocellular carcinoma in chronic hepatitis B virus infection: for whom.

Authors:  Jihyun An; Han Chu Lee
Journal:  Hepat Oncol       Date:  2015-07-28

4.  Probability-based interpretation of liver stiffness measurement in untreated chronic hepatitis B patients.

Authors:  Vincent Wai-Sun Wong; Pietro Lampertico; Victor de Lédinghen; Pik Eu Chang; Seung Up Kim; Yongpeng Chen; Henry Lik-Yuen Chan; Giampaolo Mangia; Juliette Foucher; Wan Cheng Chow; Sang Hoon Ahn; Jinlin Hou
Journal:  Dig Dis Sci       Date:  2015-01-07       Impact factor: 3.199

Review 5.  Liver cancer screening in high-risk populations.

Authors:  Morris Sherman
Journal:  Hepat Oncol       Date:  2015-11-30

6.  Liver ultrasound elastography: More than staging the disease.

Authors:  George S Gherlan
Journal:  World J Hepatol       Date:  2015-06-28

Review 7.  Virus and Host Testing to Manage Chronic Hepatitis B.

Authors:  Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Henry Lik-Yuen Chan
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

8.  Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma.

Authors:  Tai-Chung Tseng; Chun-Jen Liu; Tung-Hung Su; Wan-Ting Yang; Chi-Ling Chen; Hung-Chih Yang; Chia-Chi Wang; Stephanie Fang-Tzu Kuo; Chen-Hua Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Am J Gastroenterol       Date:  2017-08-29       Impact factor: 10.864

9.  Optimal surveillance program for hepatocellular carcinoma - getting ready, but not yet.

Authors:  Grace Lai-Hung Wong
Journal:  World J Hepatol       Date:  2015-08-28

10.  Personalized management of hepatocellular carcinoma based on molecular information: future prospects.

Authors:  Nicolas Goossens; Yujin Hoshida
Journal:  Clin Liver Dis (Hoboken)       Date:  2015-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.